Peptide Monographs

Tirzepatide

Tirzepatide is a peptide, indexed here under Incretin receptor agonists.

Identity

Measured identity values, each with the source that reports it
FieldValue
ClassificationPeptide
Primary classIncretin receptor agonists
CAS registry number2023788-19-2[1]
PubChem CID166567236[1]
UniProt accessionUnknown No UniProt query was run in v1.
Molecular formulaC225H348N48O68[1]
Molecular weight4813 g/mol[1]
Amino-acid sequenceUnknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1.
Reported half-lifeUnknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated.

What the cited literature examines

Tirzepatide is described in the retrieved literature as a dual GIP and GLP-1 receptor agonist. Its 2021 Lancet trial report characterises it in exactly those terms in patients with type 2 diabetes, and a 2021 New England Journal of Medicine trial compared it once-weekly against semaglutide once weekly in the same population.

Retrieved trial reports extend to further endpoints: a 2022 New England Journal of Medicine report on once-weekly administration in obesity, a 2024 report in metabolic dysfunction-associated steatohepatitis with liver fibrosis, and a 2025 report in heart failure with preserved ejection fraction and obesity.

[3, 4, 5, 6, 7]

Reported mechanism

Dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 receptor.

[3]

Stated in the title of the cited 2021 Lancet trial report.

Targets named in the cited records: GIP receptor, GLP-1 receptor.

FDA application register

A query of the FDA Drugs@FDA application register on 2026-10-09 returned 2 application record(s) for this compound name (including NDA215866, NDA217806, marketed as MOUNJARO, MOUNJARO KWIKPEN, MOUNJARO (AUTOINJECTOR), ZEPBOUND, ZEPBOUND KWIKPEN, ZEPBOUND (AUTOINJECTOR)). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.[2]

Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.

Retrieved 2026-10-09.

Amounts reported in the cited literature

Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.

No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.

Adverse effects reported in the cited literature

Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.

No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.

Other names

Tirzepatide appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.

Where this page sits

Research records

Cited research records for Tirzepatide, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.

Side-by-side pages that include Tirzepatide

Compounds indexed next to it

Named targets in the cited records

Class page: Incretin receptor agonists. Full index: all indexed compounds.

Questions this page answers

What does the cited literature examine for Tirzepatide?

Tirzepatide is described in the retrieved literature as a dual GIP and GLP-1 receptor agonist. Its 2021 Lancet trial report characterises it in exactly those terms in patients with type 2 diabetes, and a 2021 New England Journal of Medicine trial compared it once-weekly against semaglutide once weekly in the same population.

Which class is Tirzepatide indexed under?

Tirzepatide is indexed under Incretin receptor agonists. Incretin receptor agonists are synthetic peptides that bind one or more of the incretin and glucagon family receptors, principally the glucagon-like peptide-1 receptor.

What does the FDA application register show for Tirzepatide?

A query of the FDA Drugs@FDA application register on 2026-10-09 returned 2 application record(s) for this compound name (including NDA215866, NDA217806, marketed as MOUNJARO, MOUNJARO KWIKPEN, MOUNJARO (AUTOINJECTOR), ZEPBOUND, ZEPBOUND KWIKPEN, ZEPBOUND (AUTOINJECTOR)). Material supplied as a research chemical is not the subject of those applications and is not an FDA-approved product.

Sources

  1. PubChem Compound Summary for CID 166567236, tirzepatide. PubChem, National Library of Medicine (2026). pubchem:166567236
  2. Drugs@FDA application register query for this compound, 2 application(s) returned: NDA215866, NDA217806. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:tirzepatide
  3. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (2021). pmid:34186022
  4. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med (2021). pmid:34170647
  5. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med (2022). pmid:35658024
  6. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med (2024). pmid:38856224
  7. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med (2025). pmid:39555826

On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.

Further reading